Benita Sjogren

List of Publications by Year in Descending Order

33 papers	1,094 citations	18 h-index	33 g-index
40 ext. papers	1,303 ext. citations	4.2 avg, IF	4.19 L-index

#	Paper	IF	Citations
33	Regulator of G protein signaling 2 inhibits G□dependent uveal melanoma cell growth.. *Journal of Biological Chemistry*, **2022**, 101955	5.4	0
32	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S1-S26	8.6	20
31	N-Terminal Targeting of Regulator of G Protein Signaling Protein 2 for F-Box Only Protein 44-Mediated Proteasomal Degradation. *Molecular Pharmacology*, **2020**, 98, 677-685	4.3	2
30	Emerging Roles for Regulator of G Protein Signaling 2 in (Patho)physiology. *Molecular Pharmacology*, **2020**, 98, 751-760	4.3	3
29	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S1-S20	8.6	218
28	FBXO44-mediated RGS2 protein degradation uniquely depends on a novel Cullin 4B/DDB1 E3 ligase complex. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO4-2-62	0	
27	Chemerin-induced arterial contraction is G- and calcium-dependent. *Vascular Pharmacology*, **2017**, 88, 30-41	5.9	25
26	Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms. *Molecular Pharmacology*, **2017**, 92, 451-458	4.3	9
25	Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins. *ACS Chemical Biology*, **2017**, 12, 2240-2247	4.9	44
24	Movement disorder in encephalopathy associated with gain-of-function mutations. *Neurology*, **2017**, 89, 762-770	6.5	45
23	Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 357, 311-9	4.7	13
22	FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. *PLoS ONE*, **2015**, 10, e0123581	3.7	15
21	PKC Activation Leads to Increased RGS2 Protein Levels. *FASEB Journal*, **2015**, 29, 618.16	0.9	
20	RGS2 Protein Degradation is Mediated by a Novel Cullin 4B/F-box 44 E3 Ligase Complex. *FASEB Journal*, **2015**, 29, 618.15	0.9	
19	Identification of protein kinase C activation as a novel mechanism for RGS2 protein upregulation through phenotypic screening of natural product extracts. *Molecular Pharmacology*, **2014**, 86, 406-16	4.3	13
18	Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay. *Cellular Signalling*, **2013**, 25, 2848-55	4.9	18
17	5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. *Neuropharmacology*, **2012**, 63, 1150-60	5.5	44

List of Publications

16	Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels. *Molecular Pharmacology*, **2012**, 82, 500-9	4.3	20
15	Targeting degradation pathways of RGS2 using high-throughput siRNA screening. *FASEB Journal*, **2012**, 26, 838.9	0.9	
14	Identification of protein-protein interactions by surface plasmon resonance followed by mass spectrometry. *Current Protocols in Protein Science*, **2011**, Chapter 19, Unit19.21	3.1	15
13	Regulator of G protein signaling proteins as drug targets: current state and future possibilities. *Advances in Pharmacology*, **2011**, 62, 315-47	5.7	32
12	Regulators of G protein signaling proteins as targets for drug discovery. *Progress in Molecular Biology and Translational Science*, **2010**, 91, 81-119	4	76
11	Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. *Molecular Pharmacology*, **2010**, 78, 550-7	4.3	63
10	Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. *Experimental Cell Research*, **2010**, 316, 1351-6	4.2	31
9	RGS7 Protein Suppression of Gαo Protein-Mediated α2A-Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. *FASEB Journal*, **2010**, 24, 587.3	0.9	
8	Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions. *Nature Protocols*, **2009**, 4, 1023-37	18.8	32
7	Heat stabilization of the tissue proteome: a new technology for improved proteomics. *Journal of Proteome Research*, **2009**, 8, 974-81	5.6	125
6	Use of surface plasmon resonance coupled with mass spectrometry reveals an interaction between the voltage-gated sodium channel type X alpha-subunit and caveolin-1. *Journal of Proteome Research*, **2008**, 7, 5333-8	5.6	15
5	Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2008**, 378, 441-6	3.4	21
4	Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinsonʼs disease and identification of FKBP-12-binding proteins. *Journal of Proteome Research*, **2007**, 6, 3952-61	5.6	28
3	The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2-20 and peptides as sample quality indicators. *Proteomics*, **2007**, 7, 4445-56	4.8	96
2	Caveolin-1 affects serotonin binding and cell surface levels of human 5-HT7(a) receptors. *FEBS Letters*, **2007**, 581, 5115-21	3.8	19
1	Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. *European Journal of Pharmacology*, **2006**, 552, 1-10	5.3	52